Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

被引：0
|
作者：
James A Eastham
机构：
[1] surgeon in the Department of Urology at Memorial Sloan–Kettering Cancer Center,
来源：
Nature Clinical Practice Urology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is much debate surrounding the suitability and utility of different prognostic markers in prostate cancer. PSA doubling time (PSADT) has become an important marker in predicting the response to salvage radiotherapy and progression to metastatic disease in men with biochemical failure following local therapy. The methods of calculating PSADT and its use as a prognostic marker are discussed in this review by James Eastham.
引用
收藏
页码：482 / 491
页数：9
相关论文
共 50 条
  • [1] Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
    Eastham, JA
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (10): : 482 - 491
  • [2] The pretreatment prostate-specific antigen doubling time: clinical and prognostic values in patients with prostate cancer
    Zharinov, G. M.
    Bogomolov, O. A.
    ONKOUROLOGIYA, 2014, 10 (01): : 44 - 48
  • [3] Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer
    Kelloff, GJ
    Coffey, DS
    Chabner, BA
    Dicker, AP
    Guyton, KZ
    Nisen, PD
    Soule, HR
    D'Amico, AV
    CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3927 - 3933
  • [4] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [5] Prostate-Specific Antigen Doubling Time as a Predictor of Gleason Grade in Prostate Cancer
    Nowroozi, Mohammad Reza
    Zeighami, Shahryar
    Ayati, Mohsen
    Jamshidian, Hassan
    Ranjbaran, Ali Reza
    Moradi, Asaad
    Afsar, Firuzeh
    UROLOGY JOURNAL, 2009, 6 (01) : 27 - 30
  • [6] Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy
    Spurgeon, Stephen E. F.
    Mongoue-Tchokote, Solange
    Collins, Lauren
    Priest, Ryan
    Hsieh, Yi-Ching
    Peters, Laura M.
    Beer, Tornasz M.
    Mori, Motorni
    Garzotto, Mark
    UROLOGY, 2007, 69 (05) : 931 - 935
  • [7] Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
    Loberg, RD
    Fielhauer, JR
    Pienta, BA
    Dresden, S
    Christmas, P
    Kalikin, LM
    Olson, KB
    Pienta, KJ
    UROLOGY, 2003, 62 (6B) : 128 - 133
  • [8] Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer
    Murphy, GP
    Kenny, GM
    Ragde, H
    Wolfert, RL
    Boynton, AL
    Holmes, EH
    Misrock, SL
    Bartsch, G
    Klocker, H
    Pointner, J
    Reissigl, A
    McLeod, DG
    Douglas, T
    Morgan, T
    Gilbaugh, J
    UROLOGY, 1998, 51 (5A) : 89 - 97
  • [9] Prostate-specific antigen doubling time in metastatic castration-resistant prostate cancer: a clinically useful prognostic factor
    Colloca, G.
    Guarneri, D.
    Addamo, G.
    Venturino, A.
    Coccorullo, Z.
    Ratti, R.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (04): : 14 - 14
  • [10] TUMOR-MARKER DOUBLING TIME IN PATIENTS WITH PROSTATE-CANCER - DETERMINATION OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE DOUBLING TIME
    AKIMOTO, S
    MASAI, M
    AKAKURA, K
    SHIMAZAKI, J
    EUROPEAN UROLOGY, 1995, 27 (03) : 207 - 212
12345